KI-MSC-PL-205 / Uppsala University - LARVOL DELTA

ARDS-MSC-205: Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1 | N=7 | Completed | Sponsor: Uppsala University | Not yet recruiting ➔ Completed

Trial completion • Acute Respiratory Distress Syndrome • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

ARDS-MSC-205: Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1 | N=7 | Active, not recruiting | Sponsor: Uppsala University | Trial completion date: Jun 2025 ➔ Mar 2026

Trial completion date • Acute Respiratory Distress Syndrome • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

ARDS-MSC-205: Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1; N=7; Active, not recruiting; Sponsor: Uppsala University; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Acute Respiratory Distress Syndrome • Novel Coronavirus Disease • Respiratory Diseases • CRP • PCR

ARDS-MSC-205: Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1; N=9; Recruiting; Sponsor: Uppsala University

Clinical • New P1 trial • Acute Respiratory Distress Syndrome • Novel Coronavirus Disease • Respiratory Diseases • CRP • PCR